文献速递心外重症与机械循环支持

终末期肝病模型-排除国际标准化比值(MELD-XI)评分系统预测左心室辅助装置植入患者结局的模型

Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) Scoring System to Predict Outcomes in Patients Who Undergo Left Ventricular Assist Device Implantation.
PubMed 文献 · Ann Thorac Surg · 2018-04-04

本研究为单中心回顾性研究,纳入2004至2016年间524例植入HeartMate II或HeartWare HVAD连续流左心室辅助装置的患者,按MELD-XI评分分为<14组(n=301)和≥14组(n=223)。MELD-XI≥14组在1、3、6、12、24个月生存率更低(p均<0.001),早期右心衰竭和感染风险增加。MELD-XI预测90天死亡率不劣于HeartMate II风险评分(p=0.92)。

要点

  • MELD-XI≥14组1、3、6、12、24个月生存率均低于MELD-XI<14组(p均<0.001)。
  • MELD-XI≥14组早期右心衰竭和感染风险高于MELD-XI<14组。
  • MELD-XI预测90天死亡率不劣于HeartMate II风险评分(p=0.92)。

核心结论

  • MELD-XI评分≥14与术后死亡率高于MELD-XI评分较低者相关。
  • MELD-XI评分系统可用于预测接受连续流左心室辅助装置植入的晚期心力衰竭患者的结局。

研究设计与样本

  • 单中心回顾性研究,纳入2004年至2016年间植入HeartMate II左心室辅助装置(Thoratec Corporation, Pleasanton, CA)或HeartWare HVAD(HeartWare International Inc, Framingham, MA)的524例患者。
  • 按MELD-XI评分将患者分为两组:<14组(n=301)和≥14组(n=223)。

主要发现

  • MELD-XI≥14组在1、3、6、12和24个月生存率均低于MELD-XI<14组(p均<0.001)。
  • MELD-XI≥14组早期右心衰竭和感染风险高于MELD-XI<14组。
  • MELD-XI预测90天死亡率不劣于HeartMate II风险评分(p=0.92)。
  • 随访时MELD-XI评分升高的患者死亡率更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of continuous-flow left ventricular assist devices (CF-LVADs) to treat advanced heart failure is increasing. Although risk scores, such as Model for End-Stage Liver Disease and the HeartMate II Risk Score, require the use of the international normalized ratio, many patients are on anticoagulation before CF-LVAD implantation. This study evaluated the ability of the Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) scoring system to predict clinical outcomes in patients with advanced heart failure who undergo CF-LVAD implantation. METHODS: A single-center retrospective review was performed of 524 patients who were implanted with the HeartMate II LVAD (Thoratec Corporation, Pleasanton, CA) or the HeartWare HVAD (HeartWare International Inc, Framingham, MA) between 2004 and 2016. Patients were stratified into two cohorts: those with a MELD-XI score of less than 14 (n = 301) and 14 or higher (n = 223). RESULTS: Patients with the higher-risk MELD-XI score of 14 or higher demonstrated lower survival rates at 1, 3, 6, 12, and 24 months (p < 0.001 for all) and increased risk of early right heart failure and infections compared with patients with MELD-XI score of less than 14. MELD-XI was not significantly inferior at predicting 90-day mortality compared with the HeartMate II Risk Score (p = 0.92). Patients with elevated MELD-XI scores at follow-up demonstrated higher rates of mortality. CONCLUSIONS: These findings suggest that a MELD-XI score of 14 or higher was associated with a higher postoperative mortality rate than that seen in patients with a lower MELD-XI score. The MELD-XI scoring system can be used to predict outcomes in patients with advanced heart failure who undergo CF-LVAD implantation.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Critsinelis A, Kurihara C, Volkovicher N, et al. Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) Scoring System to Predict Outcomes in Patients Who Undergo Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2018. PMID: 29626453. doi:10.1016/j.athoracsur.2018.02.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。